Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Cash and Short-Term Investments for the year ending December 31, 2024

Ultimovacs ASA Cash and Short-Term Investments is NA for the year ending December 31, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Ultimovacs ASA Cash and Short-Term Investments for the year ending December 31, 2023 was USD 26.17 M, a -39.65% change year over year.
Ultimovacs ASA Cash and Short-Term Investments for the year ending December 31, 2022 was USD 43.36 M, a -33.32% change year over year.
Ultimovacs ASA Cash and Short-Term Investments for the year ending December 31, 2021 was USD 65.03 M, a 26.55% change year over year.
Ultimovacs ASA Cash and Short-Term Investments for the year ending December 31, 2020 was USD 51.39 M, a 12.93% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years